Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Product information and disease descriptionPlace of product in therapyDisease description

Natural history, survival, and mortality

13 evidence topics · 10 sources

Insulinoma: survival of non-metastatic and metastatic disease in a nationwide Finnish cohort

“Overall survival was analysed with Kaplan–Meier and Cox regression analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“During the follow-up, 25 (32%) patients and 63 (20%) controls deceased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In a Cox regression analysis, the median overall survival of 27.5 (95% CI: 24.1–30.8) years in the patients with a non-metastatic insulinoma did not significantly differ from the 33.2 (29.8–36.7) years in their controls (HR: 1.5 (0.9–2.6), P = 0.128).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the patients with a metastatic insulinoma, the survival was significantly impaired, with a median of 3.4 (2.9–4.0) years vs not reached in the controls (HR: 5.1 (1.9–13.3), P = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Three of the patients with metastatic insulinoma (33%), however, showed a remarkably long survival time of 6–30 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the multivariate analyses, older age and distant metastases were associated with decreased survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote